^
    Back
    Association details:
    Biomarker:BCL2 expression + MYC expression
    Cancer:Lymphoma
    Drug:methotrexate (THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2022
    Title:

    Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis

    Published date:
    11/03/2022
    Excerpt:
    In a large, retrospective cohort of PCNSL patients treated at 7 UK academic treatment centres, double expression of MYC and BCL-2 by IHC was associated with inferior PFS even in patients treated with MATRix chemotherapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1182/blood-2022-157699